Get the Stockscreener App
2.39
3.91%
+0.09
Pre-market:
2.39
Taysha Gene Therapies Inc stock is currently priced at $2.39, with a 24-hour trading volume of 890.15K.
It has seen a +3.91% increased in the last 24 hours and a -21.90% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.28 pivot point. If it approaches the $2.39 resistance level, significant changes may occur.
Previous Close:
$2.30
Open:
$2.35
24h Volume:
890.15K
Market Cap:
$446.97M
Revenue:
$15.45M
Net Income/Loss:
$-111.57M
P/E Ratio:
-1.0437
EPS:
-2.29
Net Cash Flow:
$-80.39M
1W Performance:
+5.29%
1M Performance:
-21.90%
6M Performance:
-1.65%
1Y Performance:
+264.00%
1D Range:
$2.295
$2.45
52W Range:
$0.50
$3.89
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
214 612 0000
Address
3000 Pegasus Park Drive, Suite 1430, Dallas
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
Benzinga
Evaluating Taysha Gene Therapies: Insights From 7 Financial Analysts
Benzinga
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Taysha Gene Therapies Inc (TSHA) Revenue 2024
TSHA reported a revenue (TTM) of $15.45 million for the quarter ending December 31, 2023.
Taysha Gene Therapies Inc (TSHA) Net Income 2024
TSHA net income (TTM) was -$111.57 million for the quarter ending December 31, 2023, a +32.80% increase year-over-year.
Taysha Gene Therapies Inc (TSHA) Cash Flow 2024
TSHA recorded a free cash flow (TTM) of -$80.39 million for the quarter ending December 31, 2023, a +29.02% increase year-over-year.
Taysha Gene Therapies Inc (TSHA) Earnings per Share 2024
TSHA earnings per share (TTM) was -$1.3346 for the quarter ending December 31, 2023, a +64.97% growth year-over-year.
Taysha Gene Therapies Inc Stock (TSHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Alam Kamran | Chief Financial Officer |
Aug 24 '23 |
Sale |
2.33 |
33,000 |
76,890 |
258,042 |
| Manning Paul B | 10% Owner |
Aug 16 '23 |
Buy |
0.90 |
16,466,667 |
14,820,000 |
16,466,667 |
| Nolan Sean P. | Chief Executive Officer |
Aug 16 '23 |
Buy |
0.90 |
444,444 |
400,000 |
1,535,545 |
| Stalfort John A III | Director |
Aug 16 '23 |
Buy |
0.90 |
388,889 |
350,000 |
884,290 |
| Stalfort John A III | Director |
Aug 16 '23 |
Buy |
0.90 |
388,889 |
350,000 |
999,381 |
| Donenberg Phillip B. | Director |
Aug 16 '23 |
Buy |
0.90 |
111,111 |
100,000 |
114,111 |
| Session R.A. II | 10% Owner |
Jul 13 '23 |
Sale |
0.70 |
5,344 |
3,741 |
8,871,747 |
| Session R.A. II | 10% Owner |
Jul 12 '23 |
Sale |
0.71 |
80,528 |
57,030 |
8,877,091 |
| Session R.A. II | 10% Owner |
Jun 23 '23 |
Sale |
0.70 |
18,100 |
12,735 |
8,957,619 |
| Session R.A. II | 10% Owner |
Jun 22 '23 |
Sale |
0.70 |
10,508 |
7,384 |
8,975,719 |
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
1.53%
3.38%
Cap:
|
Volume (24h):